Risks associated with use of TNF inhibitors in children with rheumatic diseases

Area of Science:

• Immunology
• Pediatric Rheumatology
• Pharmacovigilance

Background:

• Tumor necrosis factor alpha (TNF-α) is a key pro-inflammatory cytokine implicated in numerous inflammatory conditions.
• TNF-α inhibitors are increasingly utilized in pediatric rheumatology, raising safety concerns due to their immunomodulatory effects.
• Reported side effects of TNF inhibition include immunogenicity, infections, and malignancies.

Purpose of the Study:

• To evaluate the safety profile of anti-TNF-α agents in pediatric patients diagnosed with rheumatic diseases.
• To synthesize existing safety data from various study designs concerning TNF-α inhibitor use in children.

Main Methods:

• Analysis of data from retrospective and prospective safety studies.
• Review of case reports, case series, and controlled trials.
• Assessment of adverse events associated with anti-TNF-α therapy in pediatric rheumatic diseases.

Main Results:

• Anti-TNF-α agents have demonstrated a favorable safety profile in the pediatric population to date.
• The available data suggest a manageable risk-benefit ratio for these therapies in children.

Conclusions:

• While current safety data for pediatric anti-TNF-α use are reassuring, ongoing surveillance is crucial.
• Further research and vigilant monitoring are necessary to identify and address any potential long-term or unexpected adverse effects.